Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
alanine aminotransferase
aspartate aminotransferase
area under the curve
collagen proportionate area
histologic activity index
hepatitis C virus
morphometric image analysis
The concepts of grading and staging have been borrowed from the world of clinical oncology, where they give an idea of how quickly, or aggressively, a tumor is growing (its grade of differentiation) and how far it has spread through the body (its stage). This information is both a powerful indicator of prognosis as well as an important determinant of the most appropriate therapy.
By analogy, the “aggressiveness” of chronic hepatitis, in terms of progression to fibrosis/cirrhosis, is indicated by the degree of necroinflammation, also called the “activity” or the grade of hepatitis ; the more severe the necroinflammation, the more “aggressive” the disease. The stage is a measure of the extent of fibrosis and architectural disruption indicating how far the hepatitis has come along the path to cirrhosis.
In this chapter, grading and staging systems developed for chronic viral hepatitis are described. Other chronic inflammatory processes (eg, primary biliary cholangitis, primary sclerosing cholangitis) that might have histologic features similar to chronic hepatitis warrant separate consideration and are discussed in Chapter 26, Chapter 27 respectively. The pattern of damage and fibrosis in nonalcoholic steatohepatitis is distinct from that of chronic viral hepatitis. Grading and staging systems specific for this condition are discussed in Chapter 12 .
In the past, the term chronic active hepatitis was used to label biopsies with interface hepatitis (formerly known as piecemeal necrosis), whereas the term chronic persistent/chronic lobular hepatitis referred to biopsies with portal/lobular inflammation without significant interface hepatitis. This distinction was based on the assumption that chronic persistent/lobular hepatitis were relatively benign processes without progression to cirrhosis. Identification of the hepatitis C virus (HCV) and elucidation of its natural history has made it clear that interface hepatitis does not represent the “conditio sine qua non” for the onset of cirrhosis, which can also evolve from morphologic chronic persistent/lobular hepatitis; therefore, the old nomenclature has been abandoned. However, in terms of histologic severity, necroinflammation and fibrosis remain powerful prognostic parameters, associated with the risk of progression to cirrhosis. In chronic viral hepatitis, the extent of fibrosis in the baseline biopsy is a strong predictor of further fibrotic progression. Discovering of HCV along with the progress in therapeutic options gave rise to the need for assessing the severity of chronic hepatitis in a more objective and reproducible way, possibly amenable to statistical analysis, to facilitate testing of drug efficacy in clinical trials.
In the last two decades, staging, and at a lesser extent, grading, have been the main indications to perform a liver biopsy in subjects with chronic viral hepatitis. This information is useful in predicting short-term and long-term prognosis, deciding treatment options and their timing, and assessing changes occurring during or after any treatment. Nowadays, the need to perform a liver biopsy in subjects with chronic viral hepatitis, particularly chronic HCV infection has decreased because of the availability of direct acting antivirals that allow sustained viral response (SVR) in the majority of treated individuals. Nevertheless, including grade and stage in the final pathology report on cases of chronic viral hepatitis remains mandatory.
Several schemes of varying complexity have been proposed for grading and staging chronic viral hepatitis. The simplest method, familiar to most pathologists, consists of classifying both grade and stage in descriptive terms such as mild, moderate, and severe. The overall severity of necroinflammation and fibrosis is considered, but there are no specific rules to guide this evaluation, which remains highly subjective. In the more complex methods, the final grade and stage emerge from combining numerical scores attributed to each histologic lesion; all methods are based on similar principles, regardless of the specific criteria used ( Tables 16.1 and 16.2 ).
Grading Scheme | Parameters Scored | Scale Used | Overall Grade |
---|---|---|---|
Scheuer (1991) | Portal/periportal activity Lobular activity |
0–4 0–4 |
Reported as a sum of individual scores with a range of 0–8 |
Batts and Ludwig (1995) | Lymphocytic piecemeal necrosis Lobular inflammation and necrosis |
No activity, minimal, mild, moderate, severe No activity, minimal, mild, moderate, severe |
Severity of lesion (piecemeal or lobular) determines grade |
Ishak (1995) | Periportal or periseptal interface hepatitis (piecemeal necrosis) Confluent necrosis Focal lytic necrosis, apoptosis, focal inflammation Portal inflammation |
0–4 0–6 0–4 0–4 |
Reported as a sum of individual scores with a range of 0–18 |
Bedossa and Poynard (METAVIR, 1996) | Piecemeal necrosis Lobular necrosis |
0–3 (none, mild, moderate, severe) 0–2 (none, mild, moderate, severe) |
Overall histologic activity determined by algorithm combining piecemeal and lobular necrosis: A0 = none, A1 = mild, A2 = moderate, A3 = severe |
Staging Scheme | Stage 0 | Stage 1 | Stage 2 | Stage 3 | Stage 4 |
---|---|---|---|---|---|
Scheuer (1991) | No fibrosis | Enlarged, fibrotic portal tracts | Periportal fibrosis or portal-portal septa but intact architecture | Fibrosis with architectural distortion but no obvious cirrhosis | Cirrhosis, probable or definite |
Batts and Ludwig (1995) | No fibrosis | Portal fibrosis | Periportal fibrosis (including rare portal-portal septa) | Septal fibrosis (with architectural distortion) | Cirrhosis |
Bedossa and Poynard (METAVIR, 1996) | No fibrosis | Portal fibrosis without septa ( eSlide 16.1 , eSlide 16.2 ) |
Portal fibrosis with rare septa ( eSlide 16.3 ) |
Numerous septa without cirrhosis | Cirrhosis |
Stage 0 | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Stage 5 | Stage 6 | |
---|---|---|---|---|---|---|---|
Ishak (1995) | No fibrosis | Fibrous expansion of some portal tracts, with or without short septa ( eSlide 16.1 , eSlide 16.2 ) |
Fibrous expansion of most portal tracts, with or without short fibrous septa ( eSlide 16.3 ) |
Fibrous expansion of most portal tracts with occasional portal-portal bridging | Fibrous expansion of portal tracts with marked portal-portal as well as portal-central bridging ( eSlide 16.4 ) |
Marked bridging with occasional nodules (incomplete cirrhosis) | Cirrhosis, probable or definite |
Grading is performed semiquantitatively by assessing necroinflammatory lesions, both in the portal-periportal area (ie, portal inflammation and interface hepatitis) and in the lobular parenchyma (ie, lobular necrosis/apoptosis and inflammation). Each lesion is scored, with higher numbers coinciding with more severe lesions. The sum of the scores gives the grade of hepatitis. Bear in mind that these numbers represent ordered categories and not genuine mathematic measurements; therefore, general mathematic rules are not always applicable for statistical analysis.
Staging is an assessment of the extent and location of fibrosis and of accompanying changes in parenchymal architecture. All systems express stage on a linear numerical scale, with stage 0 (zero) corresponding to no fibrosis and the highest stage to a diagnosis of cirrhosis; definitions of the intermediate stages differ with the staging systems. Even more so than with grading, these numbers do not reflect measurements but rather progressive pathologic stages such as portal fibrosis or septal fibrosis , which are qualitative rather than quantitative parameters. Clinicopathologic studies have demonstrated that formation of fibrous bands linking adjacent portal tracts, or portal tracts to central veins, the so-called septal fibrosis or bridging fibrosis , carries the highest risk of further fibrotic progression and cirrhosis in chronic viral hepatitis. Septal or bridging fibrosis is therefore referred to as clinically significant fibrosis . The use of special stains for collagen is strongly recommended for proper staging of fibrosis; in the absence of universal guidelines, the choice of stain is a matter of personal preference.
The initial attempt at a semiquantitative scoring system was made by Knodell and colleagues, who proposed the histologic activity index (HAI), which combined the scores for grade and stage. Subsequent methods scored the stage and grade separately. The four systems currently in use include the Scheuer system; the Batts and Ludwig system, which is a modification of the Scheuer system; the METAVIR system; and the Ishak system, which is a modification of the HAI.
The HAI, proposed in a well-known study by Knodell and colleagues, was the first attempt to “(semi)quantify” the “aggressiveness” of chronic hepatitis. Developed to assess the efficacy of interferon in clinical trials on chronic viral hepatitis, it aimed to provide information in a format amenable to statistical analysis. The HAI is a total of the scores for periportal inflammation with or without bridging necrosis, lobular hepatocyte degeneration and focal necrosis, portal inflammation, and fibrosis ( Table 16.3 ). It has a wide range of values (0–22), thus providing discriminatory sensitivity for study of large cohorts as well as comparison of paired biopsies. Furthermore, the HAI uses weighted scores, thus assigning greater significance to numeric values but also giving rise to missing numbers. As an example, piecemeal necrosis may be assigned scores of 0, 1, 3, 4, 5, 6, or 10, whereas there are no scores 2, 7, 8, and 9. Thus, although marked piecemeal necrosis with bridging necrosis (6) is slightly worse than moderate piecemeal necrosis with bridging necrosis (5), the presence of multilobular necrosis (10) is much worse, thus deserving a score of 10 rather than 7, 8, or 9, which are therefore missing.
Ishak Score | Knodell Score | |
---|---|---|
Periportal or periseptal interface hepatitis (piecemeal necrosis) | Periportal ± bridging necrosis (piecemeal necrosis) | |
Absent | 0 | Absent |
Mild (focal, few portal areas) | 1 | Mild piecemeal necrosis |
Mild/moderate (focal, most portal areas) | 2 | |
Moderate (continuous around less than 50% of tracts or septa) | 3 | Moderate piecemeal necrosis (involves less than 50% of circumference of most portal tracts) |
Severe (continuous around more than 50% of tracts or septa) | 4 | Marked piecemeal necrosis (involves more than 50% of circumference of most portal tracts) |
Confluent necrosis | ||
---|---|---|
Absent | 0 | |
Focal confluent necrosis | 1 | |
Zone 3 necrosis in some areas | 2 | |
Zone 3 necrosis in most areas | 3 | |
Zone 3 necrosis plus occasional P-C bridging | 4 | |
Zone 3 necrosis plus multiple P-C bridging | 5 | Moderate piecemeal necrosis plus bridging necrosis |
Panacinar or multiacinar necrosis | 6 | Marked piecemeal necrosis plus bridging necrosis Multilobular necrosis |
Focal (spotty) lytic necrosis, apoptosis and focal inflammation | Intralobular degeneration and focal necrosis | |
---|---|---|
Absent | 0 | Absent |
One focus or less per ×10 objective | 1 | Mild (acidophilic bodies, ballooning degeneration, and/or scattered foci of necrosis in less than one third of lobules or nodules) |
Two to four foci per ×10 objective | 2 | |
Five to ten foci per ×10 objective | 3 | Moderate (involvement of one third to two thirds of lobules or nodules) |
More than ten foci per ×10 objective | 4 | Marked (involvement of more than two thirds of lobules or nodules) |
Portal inflammation | Portal inflammation | |
---|---|---|
Absent | 0 | Absent |
Mild, some or all portal areas | 1 | Mild (sprinkling of inflammatory cells in less than one third of portal tracts) |
Moderate, some or all portal areas | 2 | |
Moderate/marked, all portal areas | 3 | Moderate (increased inflammatory cells in one third to two thirds of portal tracts) |
Marked, all portal areas | 4 | Marked (dense packing of inflammatory cells in more than two thirds of portal areas) |
The Knodell score has been criticized for two main reasons. First, as initially designed, HAI combines necroinflammation with fibrosis. This is not biologically accurate and although fibrosis (stage) may be a consequence of liver cell damage and necroinflammation (grade), the two are not necessarily parallel processes. Furthermore, sequential liver biopsies may show an improvement in necroinflammation even as there is worsening of fibrosis. Second, the HAI scheme has missing numbers because of the formulation of weighted scores as explained previously. The Knodell HAI is now rarely used in its original version. A modified HAI and several other systems have been proposed, not just to overcome limitations of the HAI, but also to create systems simple enough for routine practice. A detailed analysis of advantages and disadvantages of the Knodell scoring system can be found in several authoritative publications.
Become a Clinical Tree membership for Full access and enjoy Unlimited articles
If you are a member. Log in here